(Q46438282)

English

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

scientific article published in September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

8

object named as

Angelo Ghezzi

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

author name string

Marco Capobianco

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Annalisa Rizzo

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Simona Malucchi

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Francesca Sperli

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Alessia Di Sapio

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Alessandra Oggero

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Mauro Zaffaroni

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Antonio Bertolotto

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

publication date

1 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Neurological Sciences

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

29 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

S227-9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

https://scigraph.springernature.com/pub.10.1007/s10072-008-0945-y

0 references

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18690500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10072-008-0945-Y

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18690500

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46438282&oldid=2111717536"